← Genetic Insights

MERTK

MERTK carries the instructions for a protein that helps the retina's support layer clean up worn-out pieces of the light-sensing cells each day. When a person inherits a non-working copy of MERTK from each parent, this cleanup fails and the retina slowly degenerates, causing a form of retinitis pigmentosa. MERTK-related disease tends to begin in childhood, often with night blindness, and progresses more rapidly and severely than many other forms of retinitis pigmentosa. MERTK is a rare cause of inherited retinal disease, accounting for a small share of cases overall, though it appears more often in some populations. An early-stage gene therapy trial that delivered a healthy copy of MERTK to the retina has been completed, and additional laboratory and animal research is ongoing.

Disease Category
autosomal recessive

Where things stand · Treatment

Treatment & research

As of the date of this review, no treatment targeting MERTK has been approved for general use.

Where things stand · Clinical trials

Studies that may be relevant to review

One gene-specific human trial, a Phase 1 study, delivered a healthy copy of MERTK beneath the retina to assess the safety of this approach in people with MERTK-associated retinitis pigmentosa.

Check current clinical trials for this gene — the Finder pulls live studies from ClinicalTrials.gov.

Find clinical trialsOpens the Clinical Trials Finder with this gene — you can change or remove it.

What this gene means

MERTK provides instructions for a receptor protein called MER tyrosine kinase, which sits on the surface of the retinal pigment epithelium (RPE) — the support…

MERTK provides instructions for a receptor protein called MER tyrosine kinase, which sits on the surface of the retinal pigment epithelium (RPE) — the support layer of cells behind the light-sensing cells of the retina. Every day the RPE performs a housekeeping job called phagocytosis; meaning, it engulfs and clears away the worn-out tips of the photoreceptors. The MERTK protein is essential for this daily cleanup to happen. When both inherited copies of MERTK carry disease-causing changes, the RPE can no longer clear this debris. It builds up, and the photoreceptors gradually die. MERTK-related retinal disease follows an pattern, which means a person is affected only when they have a harmful change in both copies of the gene, one from each parent.

How it may affect vision

The most common first symptom described in people with MERTK variants is nyctalopia, or difficulty seeing in dim light and at night.

The most common first symptom described in people with MERTK variants is nyctalopia, or difficulty seeing in dim light and at night. In one cohort of 25 people, symptoms began at an average age of about 9 years, with everyone noticing symptoms before age 16. The condition is generally a rod-cone dystrophy, meaning the rod cells that handle night and side vision are affected first, followed by the cone cells used for detail and color. A distinctive feature reported in MERTK disease is early breakdown of the macula, the central part of the retina responsible for sharp, straight-ahead vision. Studies describe a relatively rapid loss of retinal structure and vision. In the 25-person cohort mentioned earlier, all participants were legally blind by age 39. Early-onset cataracts behind the lens were also common, affecting close to half of that group. Progression and severity still vary from person to person, and at least one individual in the reported literature had a milder course.

What is known

It is well established that changes in both copies of MERTK cause autosomal recessive retinitis pigmentosa, also described as rod-cone dystrophy.

It is well established that changes in both copies of MERTK cause retinitis pigmentosa, also described as rod-cone dystrophy. Across a large review of inherited retinal disease, MERTK accounted for roughly 2% of cases with a severe retinal , confirming it is an uncommon but recognized cause. MERTK-related disease has been reported in families worldwide, and it appears comparatively often in some populations, such as parts of North Africa and the Middle East, where marriage between relatives can concentrate rare recessive variants. A wide range of variant types has been found, including missense changes, premature stop signals, and splicing errors. Importantly, large deletions of more than one exon (expressed region) have been reported repeatedly for MERTK, and considered a substantial part of MERTK-related retinal disease. Therefore, specialized copy-number testing is often needed to find the causative variant. Because the underlying problem starts in the RPE, MERTK has long been studied as a candidate for treatments that add a working copy of the gene, and an early-stage human trial has been completed.

What is uncertain

MERTK disease is generally considered non-syndromic, meaning it affects the eyes alone.

MERTK disease is generally considered non-syndromic, meaning it affects the eyes alone. However, in one small study three of six individuals with MERTK variants also had hearing impairment, and it is not yet clear whether this reflects a true connection to the gene or a separate, coincidental cause. The exact age of onset, speed of decline, and degree of central vision loss differ between individuals, and current natural-history studies are based on relatively small numbers of patients. Much of the promising therapeutic work — including gene correction in patient-derived cells and treatments tested in rats and monkeys — has been done in the laboratory or in animals, and does not by itself show benefit or safety in people. How well any MERTK-targeted therapy might preserve vision over the long term in humans remains an open question.

Treatment & research

As of the date of this review, no treatment targeting MERTK has been approved for general use.

As of the date of this review, no treatment targeting MERTK has been approved for general use. MERTK has, however, been an active focus of research because the disease starts in a single, accessible cell layer, the RPE. In laboratory work, scientists corrected the MERTK variant in cells grown from a patient and restored the RPE's ability to clear debris. A separate cell-based screening study identified a compound that improved this cleanup function in MERTK-mutant human RPE cells. One study, added the MERTK gene along with sustained-release Gas6 liposomes to rats belonging to the Royal College of Surgeons (RCS); these rates offer a well-known animal model of MERTK disease. The study found that this helped preserve photoreceptors. This was further tested for safety in non-human primates. Other animal research suggests that calming inflammatory immune cells called microglia may slow the degeneration, pointing to a possible additional approach. These are encouraging directions, but findings in cells and animals are not the same as a proven human treatment.

  • Correcting the MERTK defect in patient-derived cells

    Laboratory research in cultured human cells.
    What was found:
    The corrected cells regained normal MERTK protein and recovered the ability to engulf photoreceptor outer segments that mutant cells had lost.
    Why it matters:
    It demonstrates in the lab that fixing the MERTK defect can restore the RPE's key function, supporting gene- and cell-based therapy concepts.

    Limitation: This is proof-of-principle in cells and does not show benefit or safety in people.

  • Gene therapy plus Gas6 tested in animals

    Preclinical animal research.
    What was found:
    The combination preserved retinal structure and function in rats better than the gene alone, and showed long-term safety with only transient mild inflammation in monkeys.
    Why it matters:
    It provides preclinical data intended to support future clinical translation of MERTK gene therapy.

    Limitation: Results in rats and monkeys do not establish effectiveness or safety in humans.

  • A comprehensive catalog of MERTK variants in retinal disease

    Review combined with a large observational genetic cohort.
    What was found:
    They cataloged 79 variants of many types and estimated that MERTK accounts for about 2% of inherited retinal disease cases with a severe phenotype.
    Why it matters:
    It confirms MERTK as an established but uncommon cause of retinitis pigmentosa and documents the wide range of variants that can be responsible.

    Limitation: It summarizes reported cases and genotyping data rather than following patients' vision over time.

  • Natural history and imaging of MERTK-associated retinal dystrophy

    Observational human case series.
    What was found:
    Symptoms typically began around age 9 with night blindness, structural retinal loss progressed rapidly, early cataracts were common, and all patients were legally blind by 39.
    Why it matters:
    It gives patients and clinicians a clearer picture of the generally severe, early-onset course of MERTK disease and a narrow window for preserving central vision.

    Limitation: It is a single-center group of 25 people, and the authors call for prospective studies to confirm the findings.

  • Deletions as a major cause of MERTK disease

    Observational human genetic study.
    What was found:
    Fourteen variants were found in six individuals, including three multi-exon deletions; five of six had a severe early-onset phenotype, one was milder, and three had hearing impairment.
    Why it matters:
    It shows that standard sequencing can miss MERTK deletions, so deletion testing is important, and it raises a question about possible hearing involvement.

    Limitation: Only six people carried MERTK variants, too few to establish whether hearing loss is truly linked to the gene.

For family & caregivers

Because MERTK disease is inherited in an autosomal recessive pattern, both parents of an affected child are typically unaffected carriers, and siblings may…

Because MERTK disease is inherited in an pattern, both parents of an affected child are typically unaffected carriers, and siblings may wish to discuss carrier testing with a genetic counselor. MERTK-related vision loss often begins in childhood, so families may benefit from early attention to schooling, reading support, and developmental needs alongside eye care. A small study noted hearing impairment in some individuals; while a firm link to MERTK is not established, mentioning any hearing concerns to the care team is reasonable. Beyond these points, the general guidance shown on every gene page applies.

Questions to ask your clinician

Questions to bring to a retinal specialist or genetic counselor…

  • Did my genetic testing include copy-number or deletion analysis, given that large deletions are a common cause of MERTK disease?
  • Based on my specific MERTK variants and current vision, what pattern of progression has been seen in similar cases?
  • Should my central vision, macula, and any early cataract be monitored on a particular schedule?
  • Are there any signs, such as hearing changes, that would be worth watching or checking?
  • What imaging or functional tests would best track my condition over time?
  • How might I learn whether any current or future MERTK research studies could be relevant to me?

What you can do next

A confirmed genetic result is the foundation for understanding MERTK-related disease, and reviewing the specific variants with a genetic counselor or retinal…

A confirmed genetic result is the foundation for understanding MERTK-related disease, and reviewing the specific variants with a genetic counselor or retinal specialist can clarify what they mean. Because large deletions are a common cause of MERTK disease, it can be worth asking whether the testing that was done included copy-number analysis. Ongoing monitoring by a retinal specialist, using imaging and functional tests, can track changes over time and help with planning. To explore whether any studies may be relevant, RP Hope's Clinical Trials Finder lets you search with MERTK preselected rather than trying to judge eligibility on your own.

Sources

Peer-reviewed and registry references underlying this page…

  1. MERTK MER proto-oncogene, tyrosine kinase
  2. Bi-Allelic Pathogenic Variations in MERTK Including Deletions Are Associated with an Early Onset Progressive Form of Retinitis Pigmentosa
  3. MERTK-associated retinal dystrophy: clinical course and imaging
  4. Exploring copy number variations in Lebanese families with rod-cone dystrophy reveals a novel deletion in PRPF31 with haploinsufficiency
  5. MERTK mutation update in inherited retinal diseases
  6. Novel mutations in MERTK associated with childhood onset rod-cone dystrophy
  7. The genetics of rod-cone dystrophy in Arab countries: a systematic review
  8. Efficacy, Safety, and Durability of Gene Therapy for Inherited Retinal Diseases in the Pediatric Population: A Scoping Review
  9. Gene therapy clinical trials for inherited eye diseases: The pediatric perspective
  10. Preclinical Study on the Long-Term Efficacy and Safety of Sustained-Release Gas6 Liposomes Combined With MERTK Gene Therapy for Retinitis Pigmentosa
  11. Gene Correction Recovers Phagocytosis in Retinal Pigment Epithelium Derived from Retinitis Pigmentosa-Human-Induced Pluripotent Stem Cells
  12. Microglia Inhibition Delays Retinal Degeneration Due to MerTK Phagocytosis Receptor Deficiency
  13. A Human Retinal Pigment Epithelium-Based Screening Platform Reveals Inducers of Photoreceptor Outer Segments Phagocytosis
  14. MERTK missense variants in three patients with retinitis pigmentosa
  15. Unravelling the genetic basis of retinal dystrophies in Pakistani consanguineous families
  16. MERTK retinopathy: biomarkers assessing vision loss
  17. Challenges and Opportunities in the Genetic Analysis of Inherited Retinal Dystrophies in Africa, a Literature Review
  18. Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)
  19. RP Hope — Genetic Testing (Newly Diagnosed)
  20. RP Hope — Clinical Trials Finder
Support, accessibility and family guidance(the same for every gene)

This guidance applies to anyone living with an inherited retinal condition, whichever gene is involved. Anything specific to this gene is in the section above.

Ask before helping
People differ widely in what assistance they want, and it changes by task and by day. Asking first respects that, and avoids help that gets in the way.
Low-vision rehabilitation
Low-vision specialists work on practical skills and tools for the sight someone has — lighting, contrast, magnification, orientation and mobility.
Accessible technology
Screen readers, magnification, high-contrast modes and voice control are built into phones and computers. Small settings changes often help sooner than new equipment.
School and work
Accommodations are often available well before vision loss is severe. Starting the conversation early usually makes it easier.
Emotional and community support
A genetic result affects the whole family. Connecting with others living with RP helps people feel less alone with it.
Genetic counselling
A genetic counsellor can explain what a result means for relatives, and what testing options exist, without anyone being pushed into a decision.
Last reviewed: November 7, 2026Reviewer: Carin Elam

Medical disclaimer: This page is for education and navigation only — not medical advice, diagnosis, or treatment. These summaries are paraphrases of published research; always confirm details with a qualified clinician and primary sources.